Could a simple fat supplement protect preemie lungs?
NCT ID NCT07652684
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial investigates whether giving very preterm infants (born at 24-29 weeks) a daily supplement of two fatty acids—ARA and DHA—starting within three days of birth can reduce their risk of bronchopulmonary dysplasia (BPD), a chronic lung disease common in premature babies. Half of the infants receive the supplement along with standard care, while the other half receive standard care alone. The study tracks whether babies still need oxygen or breathing support at 36 weeks adjusted age.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ARA and DHA (fatty acids)
What this could lead to
If it works, this simple nutritional supplement could lower the risk of chronic lung disease in extremely preterm babies, reducing lifelong breathing problems.
What could go wrong
This is a small, early-phase trial (74 infants) at a single hospital. The supplement may not prevent BPD, and results may not apply to all preterm infants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHOPULMONARY DYSPLASIA (BPD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Papageorgiou General Hospital
RECRUITINGThessaloniki, Greece
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••